| Identification | Back Directory | [Name]
6,9,12,15,18,21-Hexaoxa-3-azadocosanoic acid, 22-[3-[[[3-[[(2E)-2-[[4-chloro-3-(trifluoromethyl)phenyl]methylene]hydrazinyl]carbonyl]-4,5,6,7-tetrahydro-6,6-dimethylbenzo[b]thien-2-yl]amino]carbonyl]phenyl]-3-(2-methoxyethyl)- | [CAS]
1453116-06-7 | [Synonyms]
6,9,12,15,18,21-Hexaoxa-3-azadocosanoic acid, 22-[3-[[[3-[[(2E)-2-[[4-chloro-3-(trifluoromethyl)phenyl]methylene]hydrazinyl]carbonyl]-4,5,6,7-tetrahydro-6,6-dimethylbenzo[b]thien-2-yl]amino]carbonyl]phenyl]-3-(2-methoxyethyl)- | [Molecular Formula]
C44H58ClF3N4O11S | [MOL File]
1453116-06-7.mol | [Molecular Weight]
943.46 |
| Hazard Information | Back Directory | [Description]
NaPi2b is primarily expressed in the small intestine, lungs, and testes and plays an important role in phosphate homeostasis. The inhibition of NaPi2b, responsible for intestinal phosphate absorption, is considered to reduce serum phosphate levels, making it a promising therapeutic approach for hyperphosphatemia | [Uses]
NaPi2b-IN-1 is a potent and orally active inhibitor of sodium-dependent phosphate transport protein 2b (NaPi2b) with an IC50 of 64 nM. NaPi2b is primarily expressed in the small intestine, lungs, and testes and plays an important role in phosphate homeostasis. NaPi2b-IN-1 has the potential for the research of hyperphosphatemia[1]. | [References]
[1] Maemoto M, et al. Discovery of Gut-Restricted Small-Molecule Inhibitors of Intestinal Sodium-Dependent Phosphate Transport Protein 2b (NaPi2b) for the Treatment of Hyperphosphatemia. J Med Chem. 2022;65(3):1946-1960. DOI:10.1021/acs.jmedchem.1c01474 |
|
|